Prot # GS-US-196-0123: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in Treatment Naive Subjects with Chr

Project: Research project

Project Details

StatusFinished
Effective start/end date12/13/10 → 12/13/13

Funding

  • Gilead Sciences, Inc (GS-US-196-0123)